Study G Risankizumab for Psoriasis
This trial is studying a new drug, risankizumab (Skyrizi), to treat moderate to severe genital and scalp psoriasis. 200 participants will receive injections of the drug for 1 year to assess safety & effectiveness.
- Scalp Psoriasis
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Has the FDA approved the use of Risankizumab as part of Study G?
"There is abundant evidence indicating the safety of Study G Risankizumab, thus it attained a score of 3. This trial is classified as Phase 4, signifying that this medication has received regulatory approval."
For what size of a cohort is this experiment recruiting?
"Indeed, the information on clinicaltrials.gov affirms that this research is presently engaging participants. This trial was first posted on August 9th 2023 and has been recently modified as of October 11th 2023. Currently it is enrolling 200 patients at 1 medical facility."
Are there remaining vacancies for participants of this experiment?
"Affirmative. According to data posted on clinicaltrials.gov, this medical trial is presently accepting participants; it was first published on August 9th 2023 and its most recent revision occurred two days later. The study requires 200 patients from a single site for full completion."
What objectives are researchers trying to attain with this experiment?
"This trial aims to measure the percentage of participants with an Investigator Global Assessment (IGA) score of 0 or 1 at Week 16. Secondary objectives involve measuring participant quality-of-life through Dermatology Life Quality Index (DLQI), gauging itch intensity on a numerical rating scale, and capturing sexual frequency data via Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ)."